ArticleJournal of thoracic disease2018

Durvalumab showed long and durable effects after chemoradiotherapy in stage III non-small cell lung cancer: results of the PACIFIC study.

Takehiro Uemura et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.